Search Result
Results for "
pancreatic β
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
7
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-124735
-
|
|
Others
|
Metabolic Disease
|
|
RH01687 is a compound that can protect pancreatic β cells against endoplasmic reticulum stress-induced cell death. RH01687 has the potential for the research of diabetes .
|
-
-
- HY-12462
-
|
|
Others
|
Inflammation/Immunology
|
|
WS3 is a novel proliferative molecule that promotes pancreatic β cell proliferation in rodent and human primary islets. WS3 can be used for the research of type 1 diabetes .
|
-
-
- HY-B0254
-
|
CP 28720; K 4024
|
Potassium Channel
|
Metabolic Disease
Cancer
|
|
Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
|
-
-
- HY-B0254R
-
|
|
Potassium Channel
|
Metabolic Disease
|
|
Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans .
|
-
-
- HY-109030
-
|
HMS5552
|
Glucokinase
|
Metabolic Disease
|
|
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .
|
-
-
- HY-P1156
-
-
-
- HY-N9363
-
|
|
Others
|
Metabolic Disease
|
|
Corymbiferin is one of active constituents, responsible for anti-diabetic properties. Corymbiferin improves antioxidant capacity and carbohydrate metabolism in diabetic rats, along with the improvement of histopathology of livers and pancreatic β cells .
|
-
-
- HY-120565
-
-
-
- HY-163652
-
|
|
Others
|
Metabolic Disease
|
|
Glicetanile is an orally active hypoglycemic agent, that stimulates the release of insulin from pancreatic beta cells, and lowers the blood sugar. Glicetanile exhibits potential in ameliorating the type 2 diabetes .
|
-
-
- HY-12074
-
|
|
GSK-3
|
Metabolic Disease
|
|
Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes .
|
-
-
- HY-P1980
-
|
|
Apoptosis
|
Metabolic Disease
|
|
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .
|
-
-
- HY-120711
-
|
ML187
|
Apoptosis
|
Metabolic Disease
|
|
BRD0476 is an inhibitor of pancreatic β-cell apoptosis with an EC50 value of 0.78 μM and a maximal inhibitory activity of 99%. BRD0476 can be used in diabetes-related research .
|
-
-
- HY-108664
-
|
|
Others
|
Metabolic Disease
|
|
MRS2957 is a P2Y6 receptor agonist that activates AMPK in pancreatic β-cells, promoting insulin secretion and reducing apoptosis, thereby holding potential as a therapeutic target for type 2 diabetes.
|
-
-
- HY-B0401A
-
|
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Tolbutamide sodium is a potent and orally active antidiabetic agent. Tolbutamide sodium induces apoptosis in a Ca 2+ dependent manner in pancreatic β-cells. Tolbutamide sodium has the potential for the research of non-insulin-dependent diabetes mellitus .
|
-
-
- HY-N7729
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .
|
-
-
- HY-147503
-
|
|
Apoptosis
|
Cardiovascular Disease
|
|
Vin-F03 is a potent pancreatic β-cells protective agent with an EC50 of 0.27 μM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ (HY-13753)-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research .
|
-
-
- HY-147502
-
|
|
Apoptosis
|
Cardiovascular Disease
|
|
Vin-C01 is a potent pancreatic β-cells protective agent with an EC50 of 0.22 μM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ (HY-13753)-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research .
|
-
-
- HY-109030R
-
|
HMS5552 (Standard)
|
Glucokinase
|
Metabolic Disease
|
|
Dorzagliatin (Standard) is the analytical standard of Dorzagliatin. This product is intended for research and analytical applications. Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .
|
-
-
- HY-W104821
-
|
|
Keap1-Nrf2
|
Metabolic Disease
|
|
Rosolic Acid is an activator of Nrf2, as well as its downstream targets. Rosolic Acid increases the levels of angiogenic factors, decreases inflammation (TNF-α and IL-1β) and apoptotic markers (CXCL10 and CCL2). Rosolic Acid restores the function of pancreatic cells and protects endothelial cells (ECs) from endoplasmic reticulum stressed .
|
-
-
- HY-169006
-
|
|
Apoptosis
PKC
|
Cancer
|
|
Evo312 is a dose-dependent inhibitor of protein kinase CβⅠ (PKCβⅠ) (IC50 is 117.34 nM). Evo312 induces PANC-GR (acquired gemcitabine-resistant PC cells) cell cycle arrest and apoptosis by inhibiting PKCβ1 protein expression. Evo312 has antiproliferative effects in pancreatic cancer cells PANC-1 and PANC-GR cells with IC50 of 0.08 μM and 0.07 μM, and in human normal pancreatic ductal epithelial cells HPDE6-c7 with IC50 of 2.95 μM. Evo312 exhibits antitumor activity in a PANC-GR cell transplantation mouse model .
|
-
-
- HY-P1871
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .
|
-
-
- HY-108589
-
|
PNU 37883A
|
Potassium Channel
|
Neurological Disease
|
|
PNU 37883 hydrochloride (PNU 37883A) is a selective vascular ATP-sensitive potassium (Kir6, KATP) channels blocker. PNU 37883 hydrochloride has diuretic effects with specific binding in kidney and vascular smooth muscle rather than in brain or pancreatic beta cells .
|
-
-
- HY-160038
-
|
|
LXR
|
Cancer
|
|
GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies .
|
-
-
- HY-117025A
-
|
Keramamine A hydrochloride
|
GSK-3
CDK
Parasite
Proton Pump
HSV
Autophagy
|
Infection
Neurological Disease
Cancer
|
|
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 .
|
-
-
- HY-117025
-
|
Keramamine A
|
GSK-3
CDK
Parasite
Proton Pump
HSV
Autophagy
|
Infection
Neurological Disease
Cancer
|
|
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1 .
|
-
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
-
- HY-159496
-
|
|
DYRK
|
Metabolic Disease
|
|
Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .
|
-
-
- HY-B0422
-
|
A4166; Senaglinide
|
Potassium Channel
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K + channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .
|
-
-
- HY-P1871A
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .
|
-
-
- HY-P2989
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Pyruvate carboxylase is a biotin-containing enzyme that catalyzes the HCO3 − and MgATP dependent carboxylation of pyruvate to form oxaloacetate. Pyruvate carboxylase plays an essential role in controlling whole-body energetics through regulation of gluconeogenesis in the liver, synthesis of fatty acids in adipocytes, and insulin secretion in pancreatic β cells .
|
-
-
- HY-B0682
-
|
KAD-1229 free acid anhydrous; S21403 free acid anhydrous
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .
|
-
-
- HY-156243
-
|
|
Others
|
Cancer
|
|
GDI2-IN-1 (compound (+)-37) is a GDP-dissociation inhibitor beta (GDI2) inhibitor with an IC50 of 2.87 μM and a KD of 36 μM. GDI2-IN-1 exhibits excellent in vivo antitumor activity in GDI2-overexpressing pancreatic xenograft models .
|
-
-
- HY-17398
-
|
KAD-1229 anhydrous; S21403 anhydrous
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .
|
-
-
- HY-13529
-
|
LY2608204
|
Glucokinase
|
Metabolic Disease
|
|
Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC50 of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with EC50 of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes .
|
-
-
- HY-B0682A
-
|
KAD-1229; S-21403
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
|
-
-
- HY-B0422S
-
|
A4166 d5; Senaglinide d5
|
Potassium Channel
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Nateglinide-d5 is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].
|
-
-
- HY-P2501
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .
|
-
-
- HY-B0422R
-
|
A4166 (Standard); Senaglinide (Standard)
|
Potassium Channel
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Nateglinide (Standard) is the analytical standard of Nateglinide. This product is intended for research and analytical applications. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K + channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .
|
-
-
- HY-A0036
-
|
TSE-424 acetate
|
Estrogen Receptor/ERR
|
Cancer
|
|
Bazedoxifene acetate (TSE-424 acetate) is an oral, nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene acetate can be used for the research of osteoporosis. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer .
|
-
-
- HY-10108A
-
|
|
PI3K
Casein Kinase
DNA-PK
Apoptosis
|
Cancer
|
|
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
|
-
-
- HY-P99379
-
|
CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)
|
Interleukin Related
|
Cancer
|
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
|
-
-
- HY-A0031
-
|
TSE-424
|
Estrogen Receptor/ERR
|
Cancer
|
|
Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer .
|
-
-
- HY-12752A
-
|
Trimeprazine hemitartrate
|
Histamine Receptor
Influenza Virus
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Alimemazine hemitartrate (Trimeprazine hemitartrate) is an antagonist of the histamine (HA) receptor that can be taken orally and also acts as a partial agonist at other GPCR receptors. Alimemazine hemitartrate has effects that include anti-serotonin, antispasmodic, antihistamine, sedation, hypnotic, antiviral, and anti-nausea properties. Alimemazine hemitartrate promotes the growth of pancreatic β-cells in mice and improves diabetes in mice .
|
-
-
- HY-B0254S
-
|
|
Potassium Channel
|
Metabolic Disease
|
|
Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].
|
-
-
- HY-B0682S2
-
|
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].
|
-
-
- HY-167931
-
|
|
Others
|
Metabolic Disease
|
|
Cinnamohydrazide, an unsaturated carboxylic acid derivative, serves as a precursor to aspartame through enzyme-mediated amination to phenylalanine. This compound may offer potential benefits in the prevention and treatment of diabetes by facilitating insulin secretion, enhancing pancreatic β-cell function, inhibiting hepatic gluconeogenesis, promoting glucose uptake, amplifying insulin signaling pathways, delaying carbohydrate digestion and glucose absorption, and reducing protein glycation and insulin fibrillation.
|
-
-
- HY-A0031A
-
|
TSE-424 hydrochloride
|
Estrogen Receptor/ERR
|
Cancer
|
|
Bazedoxifene hydrochloride (TSE-424 hydrochloride) is an oral active, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene hydrochloride can be used for the research of osteoporosis. Bazedoxifene hydrochloride acts as an inhibitor of IL-6/GP130 protein-protein interactions. Bazedoxifene hydrochloride can be used for the research of pancreatic cancer .
|
-
-
- HY-B0682S1
-
|
|
Potassium Channel
|
Metabolic Disease
|
|
(2R)-Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].
|
-
-
- HY-160602
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
|
-
-
- HY-N13198
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
4-(4-Hydroxyphenyl)-2-butanone 4'-O-β-D-(2-O-galloyl-6-O-cinnamoyl)glucopyranoside is a pancreatic lipase inhibitor, with an IC50 value of 2.91 μM. 4-(4-Hydroxyphenyl)-2-butanone 4'-O-β-D-(2-O-galloyl-6-O-cinnamoyl)glucopyranoside can effectively reduce lipid absorption and regulate obesity-related metabolic disorders, making it useful for research on obesity .
|
-
- HY-139792
-
|
SHR117887
|
Others
|
Metabolic Disease
|
|
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
|
-
- HY-B0682AR
-
|
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide (calcium hydrate) (Standard) is the analytical standard of Mitiglinide (calcium hydrate). This product is intended for research and analytical applications. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
|
-
- HY-123929
-
|
|
MDM-2/p53
Wnt
IKK
Apoptosis
Caspase
|
Cancer
|
|
PAWI-2 is a p53-Activator and Wnt Inhibitor. PAWI-2 inhibits β3-KRAS signaling independent of KRAS. PAWI-2 selectively inhibits phosphorylation of TBK1. PAWI-2 activates apoptosis (activation of caspase-3/7), and induces PARP cleavage. PAWI-2 promotes optineurin translocation into the nucleus and causes G2/M arrest. PAWI-2 reverses cancer stemness and overcomes drug resistance in an integrin β3 KRAS-dependent human pancreatic cancer stem cells (hPCSCs). PAWI-2 inhibits growth of tumors from hPCSCs in orthopic xenograft mice model .
|
-
- HY-B0682S
-
|
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide-d8 (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].
|
-
- HY-A0031S
-
|
TSE-424-d4
|
Isotope-Labeled Compounds
Estrogen Receptor/ERR
|
Cancer
|
|
Bazedoxifene-d4 is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].
|
-
- HY-P3622
-
|
|
GCGR
|
Metabolic Disease
|
|
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .
|
-
- HY-A0031S2
-
|
TSE-424-d4 acetate
|
Estrogen Receptor/ERR
|
Cancer
|
|
Bazedoxifene-d4 (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].
|
-
- HY-A0031R
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Bazedoxifene (Standard) is the analytical standard of Bazedoxifene. This product is intended for research and analytical applications. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer .
|
-
- HY-A0036R
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Bazedoxifene (acetate) (Standard) is the analytical standard of Bazedoxifene (acetate). This product is intended for research and analytical applications. Bazedoxifene acetate (TSE-424 acetate) is an oral, nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene acetate can be used for the research of osteoporosis. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer .
|
-
- HY-164595
-
|
|
Hippo (MST)
Apoptosis
AMPK
|
Metabolic Disease
|
|
IHMT-MST1-39 is an orally active inhibitor for MST kinase, with IC50 of 42 nM and 109 nM, for MST1 and MST2. IHMT-MST1-39 activates the AMPK signaling pathway in liver cells, reduces apoptosis of pancreatic β-cells. IHMT-MST1-39 ameliorates diabetes in Streptozotocin (HY-13753)-induced type 1 diabetes (T1D) mouse models .
|
-
- HY-19618
-
|
|
HDAC
HIV
Apoptosis
|
Infection
Metabolic Disease
|
|
BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency .
|
-
- HY-107535
-
|
|
GPR119
TRP Channel
|
Metabolic Disease
|
|
AS1269574 is a potent, orally available GPR119 agonist, with an EC50 of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes .
|
-
- HY-107543
-
|
|
Ras
|
Others
|
|
8-CPT-2Me-cAMP sodium is a selective activator of exchange proteins activated by cAMP (Epac), the cAMP sensitive guanine nucleotide exchange factors (GEFs) for the small GTPases Rap1 and Rap2. 8-CPT-2Me-cAMP sodium activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50> 10 μM) . 8-CPT-2Me-cAMP sodium stimulates Epac-mediated Ca 2+ release in pancreatic β-cells in vitro .
|
-
- HY-109692
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
GPR120 Agonist 5 (compound 12) is an agonist targeting GPR120 (EC50=1.2 μM). GPR120 Agonist 5 promotes the release of glucagon-like 1 (GLP-1) by binding to the GPR120 receptor, which in turn binds to its receptors on pancreatic beta cells, increasing insulin secretion and thereby lowering blood sugar levels. GPR120 Agonist 5 also helps reduce chronic low-grade inflammation, which plays an important role in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. GPR120 Agonist 5 can be used to investigate the mechanism of action of GPR120 in metabolic and inflammatory diseases .
|
-
- HY-168168
-
|
|
Others
|
Metabolic Disease
|
|
(5aS,6R,6aR)-MK-8666 is a selective GPR40 agonist with activity in promoting fatty acid-induced insulin secretion in pancreatic β cells and intestinal enteroendocrine cells. (5aS,6R,6aR)-MK-8666 has been studied for the inhibition of type 2 diabetes and has shown significant blood glucose lowering effects. Although (5aS,6R,6aR)-MK-8666 is considered to have potential inhibitory advantages, its development was stopped in Phase I clinical trials due to liver safety issues .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W104821
-
|
|
Indicators
|
|
Rosolic Acid is an activator of Nrf2, as well as its downstream targets. Rosolic Acid increases the levels of angiogenic factors, decreases inflammation (TNF-α and IL-1β) and apoptotic markers (CXCL10 and CCL2). Rosolic Acid restores the function of pancreatic cells and protects endothelial cells (ECs) from endoplasmic reticulum stressed .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1156
-
-
- HY-P1871A
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .
|
-
- HY-P1475
-
|
C-Peptide (dog)
|
Peptides
|
Metabolic Disease
|
|
C-Peptide, dog is a component of proinsulin, released from pancreatic beta cells into blood together with
insulin.
|
-
- HY-103545
-
|
Gastric inhibitory peptide (1-39) (porcine)
|
Peptides
|
Metabolic Disease
|
|
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca 2+ concentration ([Ca 2+]i), and capable of enhancing exocytosis .
|
-
- HY-P4813
-
|
|
Peptides
|
Metabolic Disease
|
|
Preptin, an osteogenic peptide product of the pancreatic beta-cell, corresponds to Asp 69-Leu 102 of pro-IGF-II .
|
-
- HY-P1980
-
|
|
Apoptosis
|
Metabolic Disease
|
|
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .
|
-
- HY-P1871
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .
|
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-P5390
-
|
|
Peptides
|
Others
|
|
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)
|
-
- HY-P2501
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .
|
-
- HY-P5390A
-
|
|
Peptides
|
Others
|
|
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.
|
-
- HY-P3622
-
|
|
GCGR
|
Metabolic Disease
|
|
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99379
-
|
CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)
|
Interleukin Related
|
Cancer
|
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0422S
-
|
|
|
Nateglinide-d5 is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].
|
-
-
- HY-B0254S
-
|
|
|
Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].
|
-
-
- HY-B0682S2
-
|
|
|
Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].
|
-
-
- HY-B0682S1
-
|
|
|
(2R)-Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].
|
-
-
- HY-B0682S
-
|
|
|
Mitiglinide-d8 (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].
|
-
-
- HY-A0031S
-
|
|
|
Bazedoxifene-d4 is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].
|
-
-
- HY-A0031S2
-
|
|
|
Bazedoxifene-d4 (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
